September 1, 2016 -- Fosun International, China’s largest conglomerate and the parent of Fosun Pharma, plans to announce a liquidity event for its healthcare assets before the end of the year. It will be an IPO or an infusion of private equity, said Fosun Chairman Guangchang Guo. Hospitals require large amounts of capital investment, and Fosun, an active M&A player, always wants more capital. In August, Fosun Pharma announced it will pay $1.3 billion for an 86% interest in India’s Gland Pharma, a maker of injectible drugs.
